Additional investigations are necessary to assess the impacts of combination inhibition of UCP2 and mTOR/HIF‐1α by targeted drugs, which may provide a novel treatment strategy for NSCLC. This evidence concerns the gene UCP2 and non-small cell lung carcinoma.